Harald E. Heemstra

Predictors of orphan drug approval in the European Union

Harald E. Heemstra, Remco L. de Vrueh, Sonja van Weely et al. · European Journal of Clinical Pharmacology · 2008 · 53 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +16

Safety-Related Regulatory Actions for Orphan Drugs in the US and EU

Harald E. Heemstra, Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse et al. · Drug Safety · 2010 · 39 citations

Pharmacy, Pharmaceutical Policy, Pharmacology +14

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study

Pieter Stolk, Harald E. Heemstra, Hubert G. M. Leufkens et al. · Orphanet Journal of Rare Diseases · 2009 · 20 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17

Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands

Marieke Heisen, M. Treur, Harald E. Heemstra et al. · Journal of Medical Economics · 2017 · 19 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17